Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab. This study aims to determine if the information from the cancer genome analysis corresponds with the effects of atezolizumab on individuals and their cancer. This is a Phase 2 study, which is undertaken after preliminary safety testing on a drug is completed, and will involve approximately 200 participants. Participants are assigned to one of 8 cohorts based on their primary tumour type: breast, lung, gastrointestinal (GI), primary unknown, genitourinary (GU), sarcoma, gynecological, and 'other' cancer types. Participants in all cohorts will receive the same dose of atezolizumab (1200 mg every 3 weeks). In the first stage for each cohort, 8 participants will be enrolled and if no participants respond to treatment, enrollment to that cohort will be closed. If 1 or more participants respond to treatment, up to 16 additional participants will be enrolled to that cohort. Participants continue on treatment until they no longer may benefit from the treatment or they decide to stop treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej w momencie podpisania zgody.
- •Nieuleczalny guz stały, przeanalizowany genetycznie i transkriptomowo (WGTA) w programie POG lub podobnym.
- •Pomyślne sekwencjonowanie guza, zatwierdzone przez zespół analityków POG i znalezione czynniki CAPTIV-8 (w tym wynik IBV ≥ 5).
- •Stan sprawności ECOG 0-2 (w stanie do samodzielnej opieki lub działalności).
- •Mierzalne ogniska choroby zgodnie z kryteriami RECIST 1.1.
- •Przewidywana długość życia co najmniej 12 tygodni.
- •Prawidłowe wyniki badań krwi: liczba neutrofili ≥1500, leukocytów >2500, płytek krwi ≥100 000, hemoglobina ≥9 g/dL.
- •Dla kobiet: stosowanie antykoncepcji o skuteczności ≥99% przez leczenie i 5 miesięcy po ostatniej dawce. Dla mężczyzn: stosowanie antykoncepcji i niepłodność nasienia przez leczenie i 5 miesięcy po.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 22, 2025
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
BC Cancer
Vancouver, Canada
University Health Network / Princess Margaret Cancer Centre
Toronto, Canada
Trial contact
Janessa Laskin, MD
Daniel Renouf, MD, MPH
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.